NICOTINELL PEPPERMINT LOZENGES nicotine (as nicotine polacrilex) 4 mg lozenge blister pack

País: Austrália

Língua: inglês

Origem: Department of Health (Therapeutic Goods Administration)

Ingredientes ativos:

nicotine polacrilex, Quantity: 26.66 mg (Equivalent: nicotine, Qty 4 mg)

Disponível em:

Orion Laboratories Pty Ltd T/A Perrigo Australia

DCI (Denominação Comum Internacional):

Nicotine polacrilex

Forma farmacêutica:

Tablet, uncoated

Composição:

Excipient Ingredients: mannitol; sodium carbonate; aspartame; potassium bicarbonate; sodium alginate; xanthan gum; magnesium stearate; Flavour

Via de administração:

Buccal

Unidades em pacote:

168, 36, 288, 216, 120, 132, 144, 72, 96, 108, 156

Tipo de prescrição:

Not Scheduled after consideration by Committee

Indicações terapêuticas:

Relief of nicotine withdrawal symptoms including cravings associated with smoking cessation. Nicotine Lozenges may also be used as part of a smoking reduction strategy by smokers who are unable or not ready to stop smoking abruptly as a step towards stopping smoking. If possible, when stopping smoking, should be used in conjunction with behavioural support program.

Resumo do produto:

Visual Identification: Cream/white embossed biconvex round tablet with a peppermint odour. Embossed with ?L873? on one face; Container Type: Blister Pack; Container Material: PVC/PCTFE (Aclar)/Al; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius

Status de autorização:

Licence status A

Data de autorização:

2016-06-23